Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adverse drug reaction
antidepressant
behavior modification
complications
concentration, impaired
conversion reaction
depression
diagnostic criteria
disability, neurological
dizziness
drug induced neurologic disorders
efficacy
episodic disorders
gait disorder
iatrogenic neurologic disorders
imbalance
imbalance, postural
movement disorder, psychogenic
neurologic disease, diagnoses of
Parkinson disease
paroxetine
pathologic reflex
patient information and support
Persistent postural-perceptual dizziness
precipitating factors
prognosis
safety
selective norepinephrine reuptake inhibitor
selective serotonin reuptake inhibitors
serotonin norepinephrine reuptake inhibitors
serotonin syndrome
treatment of neurologic disorder
triptans
venlafaxine
Showing articles 300 to 350 of 1008 << Previous Next >>

Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014

Association of Cerebral Microbleeds with Mortality in Stroke Patients Having Atrial Fibrillation
Neurol 83:1308-1315,1304, Song, T.J.,et al, 2014

Prosopometamorphopsia and Facial Hallucinations
Lancet 384:1998, Blom, J.D.,et al, 2014

Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency
JAMA 310:2435-2442, Lam, J.R.,et al, 2013

Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013

Edoxaban Versus Warfarin in Patients with Atrial Fibrillation
NEJM 369:2093-2104, Giugliano, R.P.,et al, 2013

Serotonin Syndrome Associated with Clozapine Withdrawal
JAMA Neurol 70:1054-1055, Stevenson, E.,et al, 2013

Sarcoidosis Presenting as Longitudinally Extensive Myelitis
Neurol 81:e61, Goenka, N. & Venna N., 2013

Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013

Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013

Reduction in Early Stroke Risk in Carotid Stenosis with Transient Ischemic Attack Associated with Statin Treatment
Stroke 44:2814-2820, Merwick, A.,et al, 2013

The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Should Statins be Paused or Discontinued After Thrombolysis or Acute Intracerebral Hemorrhage? No!
Stroke 44:1472-1476, Scheitz, J.F.,et al, 2013

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Statin Therapy should not be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2060-2061,2062, Bustamante, A. & Montaner, J., 2013

Statin Therapy should be Discontinued in Patients with Intracerebral Hemorrhage
Stroke 44:2058-2059,2062, Goldstein, L., 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012

Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012

Intracraial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation with Warfarin or Dabigatran
Stroke 43:1511-1517, Hart, R.G.,et al, 2012

High-Dose Statins should be Used in All Acute Ischemic Strokes
Stroke 43:1992-1993, 1996, Moonis, M., 2012

High-Dose Statins Should Only Be Used in Atherosclerotic Strokes
Stroke 43:1994-1995,1996, Furie, K.L., 2012

Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012

Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012

PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial
Lancet 380:1749-1758, Lopes, R.,et al, 2012

Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012

Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012

Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012

Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012

Management of Anticoagulation Before and After Elective Surgery
www.uptodate.com Dec. 2012, Lip, G. & Douketis, J., 2012

Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012

Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012

Sildenafil-Induced Cervical Spinal Cord Infarction
AJNR 33:e32-e33, Walden,J.E. & Castillo,M., 2012

Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults
Neurol 78:1337-1345, Silberstein,S.D.,et al, 2012

Treatment of Behcets Disease
UpToDate, Jan, Smith, E.L. & Yazici, Y., 2012

Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

Statin Use During Ischemic Stroke Hospitalization is Strongly Associated with Improved Poststroke Survival
Stroke 43:147-154, Flint, A.C.,et al, 2012

Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012

Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012

Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012

Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012



Showing articles 300 to 350 of 1008 << Previous Next >>